Status:
UNKNOWN
Treatment of Calculous Pyonephrosis With 0.5% Iodophors for I-stage PCNL
Lead Sponsor:
Tongji Hospital
Conditions:
Urolithiasis
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Calculous Pyonephrosis is a special type of urinary tract calculi, which is also common in clinical practice. If pyonephrosis is not treated in time, it will have a serious impact on the kidney functi...
Detailed Description
Calculous Pyonephrosis is a special type of urinary tract calculi, which is also common in clinical practice. If pyonephrosis is not treated in time, it will have a serious impact on the kidney functi...
Eligibility Criteria
Inclusion
- Age (\>18) at the time of admission;
- Glomerular filtration rate (GFR) \> 30 ml/min
- Upper urinary tract calculi with ipsilateral pyogenic infection of renal collecting system
- No fear of cold and fever or low temperature(\<36°C) before operation;
- According to the medical principle, PCNL treatment indications were given.
- Leukocyte count was (4-12) 10\^9/l. (Note: The above conditions should be met at the same time.)
Exclusion
- Complicated with severe cardiopulmonary and cerebrovascular diseases, coagulation dysfunction, hypertension, diabetes, etc.
- iodine allergy;
- lonely kidney or transplanted kidney;
- Pregnancy patients;
- those with hyperthyroidism, hypothyroidism or abnormal thyroid function;
- Other matters that are taboo for operation.
Key Trial Info
Start Date :
August 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2020
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT03805542
Start Date
August 1 2019
End Date
August 1 2020
Last Update
August 7 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030